Cash figures as of 2025-06-30. Database snapshot: 2026-09-21.
Price history
Loading IMRN daily closes…
Loading price history…
Pipeline assets
IMM-124E
Stage not disclosed · ActiveModality: polyclonal antibody (hyper-immune bovine colostrum)
Indications
Traveler's diarrhea(Stage not disclosed)
Status note Lead prescription product candidate based on hyper-immune colostrum technology. In clinical trials (phase not stated in the excerpts); company plans to commence new trials for Traveler's Diarrhea. All other current product candidates besides IMM-124E and IMM-529 are preclinical.
IMM-529
Stage not disclosed · ActiveModality: polyclonal antibody (hyper-immune bovine colostrum)
Target C. difficile
Indications
C. difficile(Stage not disclosed)
Status note Hyper-immune colostrum product candidate for C. difficile; in clinical trials (phase not stated); company plans to commence new trials.
Per-asset detail extracted from the 20-F filed 2025-12-24. Fields the filing does not state are marked "not disclosed" rather than filled from other sources.
No lead program on file for this company.
No active ClinicalTrials.gov trials matched to this company as sponsor or collaborator.
No specialist-fund holders in 13F data for this company.
Get the weekly biotech catalyst rundown. Cash runways, financings, and trial readouts for all 714 stocks.